"Cardioprotection"--not all calcium antagonists are created equal: second round.
In contrast to short-acting dihydropyridine calcium antagonists, heart-rate lowering calcium antagonists have been shown to be beneficial in some patients for prevention of reinfarction. The study of Hansen et al in this present issue shows that the addition of verapamil to trandolapril reduces event rates by >60% in patients after myocardial infarction who are in congestive heart failure. These findings are provocative and should be corroborated in a perspective, randomized trial.